LCT led to a 39.4% reduction in the risk of disease progression or death and a 53.3% reduction in the risk of death for oligo-residual NSCLC patients following effective first-line PD-1/PD-L1 inhibitors treatment. The gene discussed is CD274; the disease is non-small cell lung carcinoma.